Alternative venlafaxine kinetics in overdose

Research output: Contribution to journalArticle

Standard

Alternative venlafaxine kinetics in overdose. / Langford, Nigel; Martin, Una; Ruprah, M; Ferner, Robin.

In: Journal of Clinical Pharmacy and Therapeutics, Vol. 27, No. 6, 01.12.2002, p. 465-467.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

Langford, Nigel ; Martin, Una ; Ruprah, M ; Ferner, Robin. / Alternative venlafaxine kinetics in overdose. In: Journal of Clinical Pharmacy and Therapeutics. 2002 ; Vol. 27, No. 6. pp. 465-467.

Bibtex

@article{b1f5065816cc4fc9b80925ca07d8010d,
title = "Alternative venlafaxine kinetics in overdose",
abstract = "The pharmacokinetics of venlafaxine in therapeutic doses is well established. It is metabolized by the cytochrome P450 enzymes including CYP2D6. The toxicokinetics in overdose is less well known. Case report: A 33-year-old Caucasian female who ingested 3.0 g venlafaxine, and 210 mg zolpidem. The patient remained symptomatic for the following 24 h. Plasma pharmacokinetic analysis demonstrated a prolonged elimination half-life of venlafaxine, estimated to be 15.3 h. We postulate that the patient was a slow metabolizer of substrates for CYP2D6, an enzyme known to exhibit polymorphism.",
keywords = "metabolism, CYP2D6, overdose, pharmacokinetics, venlafaxine",
author = "Nigel Langford and Una Martin and M Ruprah and Robin Ferner",
year = "2002",
month = dec,
day = "1",
doi = "10.1046/j.1365-2710.2002.00438.x",
language = "English",
volume = "27",
pages = "465--467",
journal = "Journal of Clinical Pharmacy and Therapeutics",
issn = "0269-4727",
publisher = "Wiley",
number = "6",

}

RIS

TY - JOUR

T1 - Alternative venlafaxine kinetics in overdose

AU - Langford, Nigel

AU - Martin, Una

AU - Ruprah, M

AU - Ferner, Robin

PY - 2002/12/1

Y1 - 2002/12/1

N2 - The pharmacokinetics of venlafaxine in therapeutic doses is well established. It is metabolized by the cytochrome P450 enzymes including CYP2D6. The toxicokinetics in overdose is less well known. Case report: A 33-year-old Caucasian female who ingested 3.0 g venlafaxine, and 210 mg zolpidem. The patient remained symptomatic for the following 24 h. Plasma pharmacokinetic analysis demonstrated a prolonged elimination half-life of venlafaxine, estimated to be 15.3 h. We postulate that the patient was a slow metabolizer of substrates for CYP2D6, an enzyme known to exhibit polymorphism.

AB - The pharmacokinetics of venlafaxine in therapeutic doses is well established. It is metabolized by the cytochrome P450 enzymes including CYP2D6. The toxicokinetics in overdose is less well known. Case report: A 33-year-old Caucasian female who ingested 3.0 g venlafaxine, and 210 mg zolpidem. The patient remained symptomatic for the following 24 h. Plasma pharmacokinetic analysis demonstrated a prolonged elimination half-life of venlafaxine, estimated to be 15.3 h. We postulate that the patient was a slow metabolizer of substrates for CYP2D6, an enzyme known to exhibit polymorphism.

KW - metabolism

KW - CYP2D6

KW - overdose

KW - pharmacokinetics

KW - venlafaxine

UR - http://www.scopus.com/inward/record.url?scp=18744380007&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2710.2002.00438.x

DO - 10.1046/j.1365-2710.2002.00438.x

M3 - Article

C2 - 12472987

VL - 27

SP - 465

EP - 467

JO - Journal of Clinical Pharmacy and Therapeutics

JF - Journal of Clinical Pharmacy and Therapeutics

SN - 0269-4727

IS - 6

ER -